<DOC>
	<DOCNO>NCT02116699</DOCNO>
	<brief_summary>Extremely premature ( BW &lt; 1250g ) infant high risk morbidity mortality . Own mother 's colostrum ( OMC ) milk ( OMM ) protect neonatal morbidity rich immune factor may provide immunostimulatory effect administer oropharyngeally extremely premature infant first week life . The investigator hypothesize infant receive oropharyngeal mother 's colostrum milk significantly low rate infection improve health outcome , compare infant receive placebo .</brief_summary>
	<brief_title>Oropharyngeal Administration Mother 's Colostrum Premature Infants</brief_title>
	<detailed_description>Extremely premature ( BW &lt; 1250g ) infant high risk morbidity mortality . Own mother 's colostrum ( OMC ) milk ( OMM ) protect neonatal morbidity rich immune factor may provide immunostimulatory effect administer oropharyngeally extremely premature infant first week life . This 5-year placebo-controlled , double-blind randomize controlled trial evaluate safety , efficacy health outcome oropharyngeal administration OMC/OMM sample 622 ( total patient enrol ) extremely premature infant follow aim : Aim 1 . To determine oropharyngeal administration OMC/OMM extremely premature infant reduce risk late-onset sepsis death primary outcome , necrotizing enterocolitis ventilator-associated pneumonia pre-planned secondary outcome . Aim 2 : To determine extremely premature infant receive OMC/OMM via oropharyngeal route short time reach full enteral feed shorter length hospital stay . Aim 3 : To determine oropharyngeal administration OMC/OMM immunostimulatory effect extremely premature infant , measure ( A ) enhancement gastrointestinal ( fecal ) microbiota , ( B ) improvement antioxidant defense maturation reduction pro-oxidant status , ( C ) maturation immunostimulatory effect measure change urinary lactoferrin . Results confirm whether extremely premature infant demonstrate host-immune response intervention whether beneficial effect common morbidity high risk patient .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Pneumonia , Ventilator-Associated</mesh_term>
	<mesh_term>Enterocolitis</mesh_term>
	<mesh_term>Enterocolitis , Necrotizing</mesh_term>
	<criteria>Birthweight &lt; 1250g Mother plan pump provide breastmilk least 2 month Absence congenital anomaly Admission neonatal intensive care unit within 24 hour birth Ability begin protocol within 96 hour life Gastrointestinal anomaly Birth asphyxia ( pH &lt; 7.0 ) Maternal +HIV status Maternal drug substance use precludes infant receive mother 's milk Tracheoesophageal fistula</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>4 Days</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>oropharyngeal</keyword>
	<keyword>colostrum</keyword>
	<keyword>mother 's milk</keyword>
	<keyword>premature</keyword>
	<keyword>neonate</keyword>
	<keyword>infection</keyword>
	<keyword>necrotizing enterocolitis</keyword>
	<keyword>ventilator-associated pneumonia</keyword>
	<keyword>breastmilk</keyword>
	<keyword>human milk</keyword>
	<keyword>late-onset sepsis</keyword>
	<keyword>microbiome</keyword>
	<keyword>antioxidant</keyword>
	<keyword>enteral feed</keyword>
</DOC>